Investors pile into Bayer €2bn dual tranche hybrids
◆ German pharma's first public euro bond deal since 2024 ◆ Peak combined demand reaches €9bn ◆ Corporate hybrid issuance on track for record year
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts